Q1 earnings are due to be out on Monday, April 28. As of writing, that’s less than 24 hours away. Analysts expect a modest ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Investors will focus on lead drug Cabometyx’s performance when Exelixis EXEL reports first-quarter 2025 results shortly. The ...

Very large US-based firms now dominate in global profits. Yet this has not translated into productive investment rates in the ...

Bristol-Myers Squibb is trading near all-time high dividend and free cash flow yields. Learn why BMY stock is a Buy.

Wall Street bosses are thought to have suggested that only by firing Navarro, can some semblance of normality return.

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

Bristol-Myers Squibb is undervalued with a 5%+ dividend yield, robust pipeline, and recession-resistant business. Click here ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

Companies like Reliance Industries, Maruti Suzuki, Hindustan Zinc, RBL Bank, Shriram Finance, Tata Tech, Tejas Network, and ...

The White House has hinted that its first trade deal could be with South Korea, saying that the talks are progressing faster ...